A Review on Application of Quality by Design (QbD) Principles to the Development of Age-Appropriate Pediatric Ondansetron Formulations
Abstract
Ondansetron, a foundational 5-HT3 receptor antagonist, plays a crucial role in managing chemotherapy-induced, post-operative, and acute gastroenteritis-related vomiting in children. Despite its widespread use, significant challenges persist, notably the absence of established safety and efficacy data for children younger than four years. Furthermore, marked age-dependent pharmacokinetic (PK) variability, characterized by reduced drug clearance in neonates, mandates flexible, weight-based dosing to prevent overexposure. This review applies the Quality by Design (QbD) framework (ICH Q8(R2)) to develop age-appropriate ondansetron formulations (ODF or oral solution), establishing the Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), and Control Strategy (ICH Q10). Through proactive Quality Risk Management (QRM) and Failure Mode and Effects Analysis (FMEA), it ensures the product’s safety, efficacy, and lifecycle quality control.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.